BOSTON and LAUSANNE,
Switzerland, April 26, 2022 /PRNewswire/ -- SOPHiA GENETICS
(Nasdaq: SOPH), a leader in data-driven medicine, has reached
the milestone of one million genomic profiles analyzed by its
SOPHiA DDM™ Platform, securing its position as one of the
largest knowledge sharing platforms connecting thousands of
healthcare professionals and researchers across more than 70
countries.
Founded in 2011, SOPHiA GENETICS set out to create a world where
every clinician has a multidimensional understanding of diseases by
integrating data and sharing insights for the benefit of patients
across the globe. What began as a research tool for hospitals and
research labs, has since evolved into the SOPHiA DDM™ Platform
of today – a collaborative community of thousands of healthcare
specialists. Since launch, the platform has grown exponentially,
analyzing 39 to 70 percent more patient profiles year-over-year. It
took SOPHiA GENETICS five years to hit the milestone of 500,000
genomic profile analyses and just under two years to double
that.
Having facilitated the analysis of one million genomic profiles,
the SOPHiA DDM™ Platform has been exposed to a highly diverse
array of genomic variants needed to continually hone machine
learning algorithms for the accurate detection of rare and
challenging cases. By then sharing these insights, users across the
growing SOPHiA DDM™ Community can save time pulling the right
signal from the noise to reveal what matters most and help make
better-informed decisions for their patients.
Powered by AI and machine learning, the cloud-based SOPHiA DDM™
Platform was designed to scale, enabling the company to compute
more data, support additional data modalities, expand to new
geographies, and deploy new applications including added
capabilities to longitudinally follow patient's data while being
treated for cancer. Since its inception in genomics, the SOPHiA
DDM™ Platform has evolved to include the analysis of clinical,
biological, genomic, and radiomic data to support the numerous
ongoing multimodal studies supported by SOPHiA GENETICS. The
company is also collaborating with GE Healthcare to advance cancer
care by better targeting and matching treatment to a patient's
genomic profile and cancer type.
"Since launching our SOPHiA DDM™ platform, it has become
clear that our vision to bridge science and technology to turn
complex multimodal data into valuable insights is resonating among
healthcare institutions and their patients globally," said Jurgi
Camblong, co-founder and CEO of SOPHiA GENETICS. "They see the
value of our collaborative, decentralized platform that breaks down
data silos to provide equal access to knowledge and capabilities
for the benefit of patients worldwide. I am very proud of this
incredible milestone and look forward to the continued growth and
diversity of our network."
To learn more about how SOPHiA GENETICS' data-driven insights
are improving diagnosis, treatment, and drug development for
patients and the larger medical community,
visit www.sophiagenetics.com.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH)
is a health care technology company dedicated to establishing the
practice of data-driven medicine as the standard of care and for
life sciences research. It is the creator of the SOPHiA DDM™
Platform, a cloud-based SaaS platform capable of analyzing data and
generating insights from complex multimodal data sets and different
diagnostic modalities. The SOPHiA DDM™ Platform and related
solutions, products and services are currently used by more than
790 hospital, laboratory, and biopharma institutions globally. For
more information, visit www.sophiagenetics.com, or connect on
Twitter, LinkedIn and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenertics.com to obtain
the appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking Statements:
This
press release contains statements that constitute forward-looking
statements. All statements other than statements of historical
facts contained in this press release, including statements
regarding our future results of operations and financial position,
business strategy, products and technology, as well as plans and
objectives of management for future operations, are forward-looking
statements. Forward-looking statements are based on our
management's beliefs and assumptions and on information currently
available to our management. Such statements are subject to risks
and uncertainties, and actual results may differ materially from
those expressed or implied in the forward-looking statements due to
various factors, including those described in our filings with the
U.S. Securities and Exchange Commission. No assurance can be given
that such future results will be achieved. Such forward-looking
statements contained in this press release speak only as of the
date hereof. . We expressly disclaim any obligation or undertaking
to update these forward-looking statements contained in this press
release to reflect any change in our expectations or any change in
events, conditions, or circumstances on which such statements are
based, unless required to do so by applicable law. No
representations or warranties (expressed or implied) are made about
the accuracy of any such forward-looking statements.
![SOPHiA GENETICS Logo SOPHiA GENETICS Logo](https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg)
Video
- https://mma.prnewswire.com/media/1804161/GIF_1Million_2022_v2.mp4
Logo
- https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg